EDIT vs EFX · rev $32.3M vs P/E 54, rev $5.68B
Editas Medicine Inc (EDIT) versus Equifax Inc (EFX) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Equifax Inc (EFX) is a consulting services company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
EDIT currently screens at market cap $375.2M. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Not investment advice. Open the EDIT and EFX stock pages for the full models.
Not investment advice.